Form 4 for TARA Protara Therapeutics, Inc.
Accepted 2023-01-20 00:00:00 ET · period of report 2023-01-19 · accession 0001213900-23-004081 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-20 | 2023-01-19 | TARA | Shefferman Jesse | CEO, Pres, Dir | A - Grant | $0.00 | +51.3K | 918.3K | +6% | $0 |
| D | 2023-01-20 | 2023-01-19 | TARA | Shefferman Jesse | CEO, Pres, Dir | A - Grant | $0.00 | +307.5K | 307.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-19 | A | A | 51,300 | $0.00 | 918,282 | D | — | — | (F1) The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 19, 2023. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-01-19 | A | A | 307,500 | $0.00 | 307,500 | D | $3.02 · — to 2033-01-18 | 307,500 Common Stock | (F2) 25% of the shares vest on the one year anniversary of January 19, 2023 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. |